Earlier, the term NAFLD (Non-Alcoholic Fatty Liver Disease) was renamed MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease).
The new name highlights the connection between the fatty liver disease and the metabolic problems, such as obesity, type 2 diabetes, and abnormal cholesterol levels.
MASLD affects about 25 per cent of people globally, with rates rising to 50–70 per cent in those with type 2 diabetes or obesity.